{"id":5484,"date":"2015-07-29T13:49:13","date_gmt":"2015-07-29T17:49:13","guid":{"rendered":"http:\/\/geiselmed.dartmouth.edu\/news\/?p=5484"},"modified":"2015-09-08T11:10:04","modified_gmt":"2015-09-08T15:10:04","slug":"dartmouth-receives-nih-grant-to-launch-new-northeast-node-of-national-drug-abuse-clinical-trials-network","status":"publish","type":"post","link":"https:\/\/geiselmed.dartmouth.edu\/news\/2015\/dartmouth-receives-nih-grant-to-launch-new-northeast-node-of-national-drug-abuse-clinical-trials-network\/","title":{"rendered":"Dartmouth Receives NIH Grant to Launch Northeast Node of National Drug Abuse Clinical Trials Network"},"content":{"rendered":"

The National Institute on Drug Abuse <\/a>(NIDA) has awarded a five-year $3.8 million grant to Geisel School of Medicine at Dartmouth\u2019s Center for Technology and Behavioral Health<\/a>. The award will support the launch of the new Northeast Node in NIDA\u2019s National Clinical Trials Network (CTN), and clinical trials conducted by the Node will be supported by additional research project grants from NIDA, which is part of the National Institutes of Health.<\/p>\n

\u201cThere is so much energy and enthusiasm not only among the members of the team here at Dartmouth, but also among the more than 400 healthcare partners who are linked to our new Node,\u201d says Lisa Marsch, PhD<\/a>, director of the Center for Technology and Behavioral Health (CTBH), an associate professor of psychiatry, and principal investigator on the new CTN Node. CTBH is a NIDA-funded national Center of Excellence that uses science to inform the development, rigorous evaluation, and sustainable implementation of mobile and web-based therapeutic tools for substance use disorders and mental health.<\/p>\n

\"Lisa
Lisa Marsch, PhD, Director of the Center for Technology and Behavioral Health at Dartmouth (Photo by Mark Washburn)<\/figcaption><\/figure>\n

\u201cCTBH was viewed as a real value to this national network,\u201d Marsch says. \u201cThere has been very clear recognition within the national CTN and NIDA, as well as in the communities with which they work, that both mobile and web-based technology can play an enormous role in scaling up evidence-based addiction treatment.\u201d<\/p>\n

NIDA\u2019s CTN is a national network of academic researchers and community-based healthcare partners collaborating on national clinical trials to identify effective interventions for drug abuse, and how to best coordinate and translate evidence-based treatment into community-based models of care. Prior to the addition of Dartmouth, the CTN has been comprised of 13 Nodes across the U.S.<\/p>\n

\u201cThis grant accelerates the strong national presence that Lisa has established with the CTBH,\u201d says Duane Compton, Geisel School of Medicine\u2019s interim dean. \u201cHer work is at the cutting edge of using technology to impact on mental health issues and this new award will bring more clinical partners to the table to study and disseminate the best clinical practices throughout the community to treat substance addiction.\"<\/p>\n

Maine, New Hampshire, and Vermont, historically have not been represented in NIDA\u2019s national set of data or in the clinical trials that have been conducted. \u201cThis is the first time these groups will be part of the network, and we will work together on studies to integrate addiction prevention and treatment into primary care,\u201d Marsch says.<\/p>\n

\u201cOur community partners are thrilled to be part of this Node,\u201d she adds. \u201cFor example, we learned that partners in Maine wanted to be part of the national CTN since its inception, but there hasn\u2019t been a Node this far north\u2014they are excited to contribute to not only the learning, but also to applying what\u2019s learned in their own communities to develop new ways to educate providers in an effort to curb over-prescribing of long-acting prescription opioids.\u201d<\/p>\n

Prescription opioid abuse is a big problem in upper New England, and nationally. Vermont has one of the highest rates of opioid abuse in the country and Maine is a top prescriber of extended-release opioid medications\u2014potent medications that have high abuse potential\u2014which are prescribed at a higher rate per capita than in any other state, Marsch notes.<\/p>\n

\u201cThe selection of Center for Technology and Behavioral Health for this important and prestigious NIDA CTN award aimed at improving treatment and enhancing prevention of substance addiction is an important testament to Geisel\u2019s research strengths,\u201d said Alan I. Green, MD, chair of psychiatry at Geisel and director of SYNERGY, Dartmouth\u2019s Clinical and Translational Science Institute. \u201cIt recognizes Dartmouth\u2019s long-standing leadership in research related to addiction, as well as in CTBH\u2019s innovative use of technology tools in behavioral health.\u201d<\/p>\n

CTBH\u2019s work includes seminal research on the integration of substance abuse disorder interventions in rural health systems. The Center\u2019s investigators are leaders in the field of technology-based therapeutic tools for all stages of substance abuse disorders and behavioral interventions ranging from development to effectiveness to implementation. They also have expertise in research focused on cannabis and prescription opioid use disorders among adolescents.<\/p>\n

\u201cYou can create technology-based systems that can deliver a variety of digital therapeutic tools and resources for people with substance use disorders to help with prevention, treatment, and recovery support, but you have to creatively and carefully assess how to best embed them into delivery service models\u2014and I think that\u2019s a unique piece we offer to the national CTN,\u201d Marsch says.<\/p>\n","protected":false},"excerpt":{"rendered":"

The National Institute on Drug Abuse (NIDA) has awarded a five-year $3.8 million grant to Dartmouth\u2019s Center for Technology and Behavioral Health. The award will support the launch of the new Northeast Node in NIDA\u2019s National Clinical Trials Network, and clinical trials conducted by the Node will be supported by additional research project grants from NIDA, part of the National Institutes of Health.<\/p>\n","protected":false},"author":12,"featured_media":5485,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"aside","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1,8],"tags":[624,623,65,622,397,320,159],"class_list":["post-5484","post","type-post","status-publish","format-aside","has-post-thumbnail","hentry","category-news","category-research","tag-behavioral-health","tag-ctbh","tag-lisa-marsch","tag-nida","tag-nih","tag-research-2","tag-substance-abuse","post_format-post-format-aside","author-12"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-content\/uploads\/sites\/2\/2015\/07\/NIDA-CTBH.jpg","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p4r3h1-1qs","_links":{"self":[{"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/posts\/5484","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/comments?post=5484"}],"version-history":[{"count":7,"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/posts\/5484\/revisions"}],"predecessor-version":[{"id":5493,"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/posts\/5484\/revisions\/5493"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/media\/5485"}],"wp:attachment":[{"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/media?parent=5484"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/categories?post=5484"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/tags?post=5484"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}